Small-cell Lung Cancer

Oncology
12
Pipeline Programs
10
Companies
9
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
4
3
0
4
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
457%
Small Molecule
343%
+ 5 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
2 programs
1
1
AtezolizumabPhase 3Monoclonal Antibody1 trial
NivolumabPhase 1Monoclonal Antibody
Active Trials
NCT05091567Active Not Recruiting660Est. Aug 2026
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
Iparomlimab and TuvonralimabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT06789796Not Yet RecruitingEst. Mar 2030
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
TarlatamabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT07005128Recruiting330Est. Jul 2029
Zai Lab
Zai LabCA - South SF
1 program
1
ZL-1310Phase 31 trial
Active Trials
NCT07218146Recruiting480Est. Nov 2028
M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
BerzosertibPhase 2Small Molecule1 trial
GocatamigPhase 1/2
Active Trials
NCT04768296CompletedEst. Jul 2023
Oryzon Genomics
Oryzon GenomicsMA - Cambridge
1 program
1
IadademstatPhase 2Small Molecule
Genomics
GenomicsUK - Oxford
1 program
1
IadademstatPhase 2Small Molecule1 trial
Active Trials
NCT05420636Terminated20Est. Jul 2025
BT
1 program
1
CirtuvivintPhase 1/21 trial
Active Trials
NCT07155200RecruitingEst. Jan 2029
DS
Daiichi SankyoChina - Shanghai
1 program
1
GocatamigPhase 1/21 trial
Active Trials
NCT04471727Active Not Recruiting232Est. Jan 2028
IDEAYA Biosciences
IDEAYA BiosciencesSOUTH SAN FRANCISCO, CA
1 program
1
IDE849Phase 1/21 trial
Active Trials
NCT07174583Recruiting208Est. May 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Zai LabZL-1310
AmgenTarlatamab
Qilu PharmaceuticalIparomlimab and Tuvonralimab
Jazz PharmaceuticalsAtezolizumab
GenomicsIadademstat
Merck & Co.Berzosertib
Biosplice TherapeuticsCirtuvivint
IDEAYA BiosciencesIDE849
Daiichi SankyoGocatamig

Clinical Trials (9)

Total enrollment: 1,930 patients across 9 trials

NCT07218146Zai LabZL-1310

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

Start: Nov 2025Est. completion: Nov 2028480 patients
Phase 3Recruiting
NCT07005128AmgenTarlatamab

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Start: Aug 2025Est. completion: Jul 2029330 patients
Phase 3Recruiting
NCT06789796Qilu PharmaceuticalIparomlimab and Tuvonralimab

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

Start: Feb 2025Est. completion: Mar 2030
Phase 3Not Yet Recruiting
NCT05091567Jazz PharmaceuticalsAtezolizumab

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

Start: Nov 2021Est. completion: Aug 2026660 patients
Phase 3Active Not Recruiting
NCT05420636GenomicsIadademstat

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Start: Dec 2022Est. completion: Jul 202520 patients
Phase 2Terminated
NCT04768296Merck & Co.Berzosertib

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Start: Mar 2021Est. completion: Jul 2023
Phase 2Completed
NCT07155200Biosplice TherapeuticsCirtuvivint

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Start: Dec 2025Est. completion: Jan 2029
Phase 1/2Recruiting
NCT07174583IDEAYA BiosciencesIDE849

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Start: Oct 2025Est. completion: May 2029208 patients
Phase 1/2Recruiting
NCT04471727Daiichi SankyoGocatamig

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Start: Dec 2020Est. completion: Jan 2028232 patients
Phase 1/2Active Not Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 1,930 patients
10 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)